C-reactive protein is a prognostic parameter in patients with cervical cancer

被引：81

作者：

Polterauer, Stephan ^{[1
]}

Grimm, Christoph ^{[1
]}

Tempfer, Clemens ^{[1
]}

Sliutz, Gerhard ^{[1
]}

Speiser, Paul ^{[1
]}

Reinthaller, Alexander ^{[1
]}

Hefler, Lukas A. ^{[1
]}

机构：

[1] Med Univ Vienna, Dept Obstet & Gynecol, A-1090 Vienna, Austria

来源：

GYNECOLOGIC ONCOLOGY | 2007年 / 107卷 / 01期

关键词：

CRP; serum; prognosis; cervical cancer;

D O I：

10.1016/j.ygyno.2007.06.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objective. To evaluate whether C-reactive protein (CRP) serum levels can be used as a prognostic parameter in patients with cervical cancer. Methods. In the present study, CRP serum levels were measured in 215 patients with cervical cancer. CRP serum levels were measured prior to therapy for cervical cancer and were correlated to clinical data. Results. The median CPP serum level in patients with cervical cancer was 0.5 mg/dl (interquartile range 0.5-0.9 mg/dl). CRP serum levels were significantly associated with advanced tumor stage (p<0.001), lymph node involvement (p=0.01) and patients' age (p=0.01), but not with histological grade (p=0.1) and histological type (p=0.9). In a univariate and multivariate analysis CRP serum levels, tumor stage, and lymph node involvement, but not histological grade, histological type and patients' age were associated with overall and disease-free survival. Conclusion. CRP serum levels can be used as additional prognostic parameter in patients with cervical cancer. (C) 2007 Elsevier Inc. All rights reserved.

引用

页码：114 / 117

页数：4

共 33 条

[1] Inflammation and cancer: back to Virchow? [J].

Balkwill, F ;

Mantovani, A .

LANCET, 2001, 357 (9255) :539-545

[2] C-reactive protein [J].

Black, S ;

Kushner, I ;

Samols, D .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (47) :48487-48490

[3] SQUAMOUS-CELL CARCINOMA ANTIGEN - CLINICAL UTILITY IN SQUAMOUS-CELL CARCINOMA OF THE UTERINE CERVIX [J].

BOLLI, JAN ;

DOERING, DL ;

BOSSCHER, JR ;

DAY, TG ;

RAO, CV ;

OWENS, K ;

KELLY, B ;

GOLDSMITH, J .

GYNECOLOGIC ONCOLOGY, 1994, 55 (02) :169-173

[4]

BROWN DJF, 2006, J CLIN PATHOL

[5] Inflammation and cancer [J].

Coussens, LM ;

Werb, Z .

NATURE, 2002, 420 (6917) :860-867

[6] C-reactive protein and the risk of incident colorectal cancer [J].

Erlinger, TP ;

Platz, EA ;

Rifai, N ;

Helzlsouer, KJ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (05) :585-590

[7] Clinical significance of interleukin-1 receptor antagonist in patients with cervical carcinoma [J].

Fujiwaki, R ;

Iida, K ;

Nakayama, K ;

Kanasaki, H ;

Hata, K ;

Katabuchi, H ;

Okamura, H ;

Miyazaki, K .

GYNECOLOGIC ONCOLOGY, 2003, 89 (01) :77-83

[8] Can initial serum Cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis? [J].

Gaarenstroom, KN ;

Kenter, GG ;

Bonfrer, JMG ;

Korse, CM ;

Van de Vijver, MJ ;

Fleuren, GJ ;

Trimbos, JB .

GYNECOLOGIC ONCOLOGY, 2000, 77 (01) :164-170

[9] Significance of preoperative C-reactive protein as a parameter of the perioperative course and long-term prognosis in squamous cell carcinoma and adenocarcinoma of the oesophagus [J].

Gockel, Ines ;

Dirksen, Kathrin ;

Messow, Claudia M. ;

Junginger, Theodor .

WORLD JOURNAL OF GASTROENTEROLOGY, 2006, 12 (23) :3746-3750

[10]

GOCZE PM, 1994, ONCOLOGY, V51, P430

← 1 2 3 4 →